Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Yestar Healthcare : Next Day Disclosure Return - Share Buyback 2019-09-12

share with twitter share with LinkedIn share with facebook
share via e-mail
09/12/2019 | 12:12pm EDT

For Main Board listed issuers

Next Day Disclosure Return

(Equity issuer - changes in issued share capital and/or share buybacks) Name of listed issuer: Yestar Healthcare Holdings Company Limited

Stock code:


Date submitted: 12 September 2019

Section I must be completed by a listed issuer where there has been a change in its issued share capital which is discloseable pursuant to rule 13.25A of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Exchange").

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under rule 10.06(4)(a).

Description of securities: __Ordinary Shares__


Issued shares as a % of

Closing market price

% discount/

No. of shares

existing number of issued

per share of the

Issues of shares

Issue price per share

premium of issue price

shares before relevant

immediately preceding

(Notes 6 and 7)

(Notes 1 and 7)

to market price

share issue

business day

(Note 7)

(Notes 4, 6 and 7)

(Note 5)

Opening balance as at


(Note 2)

31 August 2019

(Note 3)

Share repurchase from 27



August 2019 to 11 September

2019 but not yet cancelled

Share repurchase on 12



September 2019 but not yet


Closing balance as at


(Note 8)

12 September 2019


For Main Board listed issuers

We hereby confirm to the best knowledge, information and belief that, in relation to each issue of securities as set out in Section I, it has been duly authorized by the board of directors of the listed issuer and, insofar as applicable:

(Note 9)

  1. all money due to the listed issuer in respect of the issue of securities has been received by it;
  2. all pre-conditions for the listing imposed by the Listing Rules under "Qualifications of listing" have been fulfilled;
  3. all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
  4. all the securities of each class are in all respects identical (Note 10);
  5. all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;
  6. all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
  7. completion has taken place of the purchase by the issuer of all property shown in the listing document to have purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
  8. the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Notes to Section I:

  1. Where shares have been issued at more than one issue price per share, a weighted average issue price per share should be given.
  2. Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to rule 13.25A or Monthly Return pursuant to rule 13.25B, whichever is the later.
  3. Please set out all changes in issued share capital requiring disclosure pursuant to rule 13.25A together with the relevant dates of issue. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
  4. The percentage change in the number of issued shares of listed issuer is to be calculated by reference to the listed issuer's total number of shares in issue (excluding for such purpose any shares repurchased or redeemed but not yet cancelled) as it was immediately before the earliest relevant event which has not been disclosed in a Monthly Return or Next Day Disclosure Return.
  5. Where trading in the shares of the listed issuer has been suspended, "closing market price per share of the immediately preceding business day" should be construed as "closing market price per share of the business day on which the shares were last traded".


For Main Board listed issuers

  1. In the context of a repurchase of shares:
    • "issues of shares" should be construed as "repurchases of shares"; and
    • "issued shares as a % of existing number of shares before relevant share issue" should be construed as "repurchased shares as a % of existing number of shares before relevant share repurchase".
  2. In the context of a redemption of shares:
    • "issues of shares" should be construed as "redemptions of shares";
    • "issued shares as a % of existing number of shares before relevant share issue" should be construed as "redeemed shares as a % of existing number of shares beforerelevant share redemption"; and
    • "issue price per share" should be construed as "redemption price per share".
  3. The closing balance date is the date of the last relevant event being disclosed.
  4. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases.
  5. "Identical" means in this context:
    • the securities are of the same nominal value with the same amount called up or paid up;
    • they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
    • they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.


For Main Board listed issuers


  1. Purchase report


Number of

Method of purchase

Price per share or highest




price paid $


12 Sept


On the Exchange





  1. Additional information for issuer whose primary listing is on the Exchange
  1. Number of such securities purchased on the Exchange in the year to date (since ordinary resolution)
  2. % of number of shares in issue at time ordinary resolution passed acquired on the Exchange since date of resolution

( (a) x 100 )


Lowest price paid $

Total paid $




(a) 20,400,000


We hereby confirm that the repurchases set out in A above which were made on the Exchange were made in accordance with the Listing Rules and that there have been no

material changes to the particulars contained in the Explanatory Statement dated 10 May 2019 which has been filed with the Exchange. We also confirm that any purchases set out in A above which were made on another stock exchange were made in accordance with the domestic rules applying to purchases made on that other exchange.

Note to Section II: Please state whether on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.

Submitted by:

Ng Chit Sing



Company Secretary

(Director, Secretary or other duly authorised officer



Yestar Healthcare Holdings Co. Ltd. published this content on 12 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 September 2019 16:11:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
01:17aASTELLAS PHARMA : Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
01:15aNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
01:12aHENNES & MAURITZ : H&M summer collection boosts third quarter sales growth
01:11aELDORADO GOLD : Greece seeking new mining jobs and higher royalties in talks with Canada's Eldorado Gold
01:11aAPPLE : challenge to EU over €13bn Irish tax order
01:11aATLANTIA : chief exec set to step down as bridge probe darkens
01:11aJP MORGAN CHASE MPANY : US authorities charge JP Morgan metals traders with 'racketeering'
01:11aMORGAN STANLEY : Endeavor looks to raise $712m in public listing
01:11aCUSHMAN & WAKEFIELD : City moves who's switching jobs
01:11aNATIONAL GRID : Former National Grid boss 'heads for City Fibre'
Latest news "Companies"